Managing coronary artery disease in patients with concurrent cancer requires careful procedural planning. Interventional cardiologists increasingly consider DCB angioplasty in cancer patients as an attractive alternative to drug-eluting stents. Drug-coated balloons eliminate permanent metal struts and shorten dual antiplatelet therapy. Consequently, this approach may reduce bleeding risks in frail oncology patients. However, comparative clinical data remain limited.

Clinical Dilemmas in Modern Cardio-Oncology Revascularization

Cardio-oncology has rapidly emerged as a vital discipline because oncologic therapies and shared risk factors accelerate vascular disease. Consequently, clinicians frequently encounter patients who require percutaneous revascularization while receiving chemotherapy, immunotherapy, or radiation. In these complex cases, traditional drug-eluting stents present serious management challenges. Prolonged dual antiplatelet therapy substantially increases major bleeding risks, particularly in patients experiencing tumor-induced anemia or severe thrombocytopenia. Therefore, interventional teams actively seek strategies that minimize stent thrombosis without requiring extended antiplatelet administration. Drug-coated balloons deliver antiproliferative drugs directly to the vessel wall and leave no permanent foreign metallic scaffold behind. As a result, this strategy permits significantly shorter antiplatelet durations. Nevertheless, malignant disease processes create systemic inflammation and abnormal hemodynamics that can impair vascular healing. Furthermore, competing mortality risks from cancer progression often overshadow cardiovascular interventions. Interventional cardiologists must therefore examine whether avoiding permanent stents translates into measurable survival advantages in cancer patients.

Investigating Real-World Outcomes: The Chaoyang Hospital Cohort

To evaluate real-world clinical performance, investigators at Beijing Chaoyang Hospital executed a retrospective comparative study. Specifically, researchers enrolled 155 consecutive patients hospitalized between January 2018 and December 2024. All participants had angiographically confirmed coronary artery disease and underwent percutaneous coronary intervention. Crucially, every enrolled patient had received a formal cancer diagnosis within five years prior to admission. Within this high-risk cohort, 61 patients underwent drug-coated balloon angioplasty, whereas 94 patients received drug-eluting stent implantation. The researchers systematically tracked baseline demographics, cardiovascular comorbidities, oncologic diagnoses, and detailed angiographic parameters. Furthermore, investigators analyzed procedural metrics, including acute vessel recoil, immediate post-procedural blood flow, and intravascular imaging utilization. Continuous variables were compared using independent-samples t-tests, while categorical data were evaluated through chi-square or Fisher exact tests. Additionally, the authors analyzed overall survival using Kaplan-Meier survival curves and log-rank statistics. These rigorous methodological standards provided a dependable foundation for comparing both interventional modalities.

Lesion Complexity and Anatomical Differences Between Cohorts

An analysis of baseline clinical characteristics revealed comparable distributions in age, sex, body mass index, smoking status, hypertension, and dyslipidemia. However, marked differences emerged regarding lesion complexity and anatomical presentation between the two intervention groups. Patients treated with drug-coated balloons demonstrated significantly higher rates of diabetes mellitus, triple-vessel coronary disease, and in-stent restenosis. Moreover, this group had a substantially higher incidence of bifurcation lesions and small-vessel coronary disease. Conversely, the stent cohort displayed higher proportions of previous coronary artery bypass grafting, prior percutaneous interventions, and left anterior descending artery involvement. These patterns indicate that operators preferentially selected balloon angioplasty for anatomically challenging or restenotic scenarios. Specifically, clinicians utilized drug-coated balloons to avoid stacking metallic struts in recurrent in-stent restenosis or compromising side branches. Consequently, patients receiving balloon angioplasty exhibited greater baseline vascular complexity. Interventionalists must carefully consider these anatomical disparities when interpreting subsequent patient outcomes and long-term device performance.

Evaluating DCB Angioplasty in Cancer and Survival Differences

When analyzing overall clinical outcomes, researchers observed striking survival disparities between the two revascularization strategies. Specifically, Kaplan-Meier curves demonstrated that patients undergoing DCB angioplasty in cancer experienced significantly lower overall survival than those receiving drug-eluting stents. The overall survival rate reached 82.0% in the balloon angioplasty cohort, reflecting 50 survivors among 61 patients. In contrast, the stent group achieved a 95.7% overall survival rate, with 90 survivors among 94 patients. This survival gap achieved clear statistical significance with an unadjusted p-value of 0.005. At first glance, such divergence might suggest that drug-coated balloons provide inferior procedural efficacy. However, all-cause mortality paints an incomplete picture in oncology patients, whose prognosis is often dictated by malignant disease progression. Furthermore, procedural success and acute angiographic patency remained excellent in both arms. Clinicians must therefore look beyond aggregate mortality numbers to determine the true pathophysiological mechanisms behind this survival difference.

Competing Risk Analysis: Cardiovascular Versus Non-Cardiac Causes

To resolve the underlying reasons for the survival difference, investigators performed a competing risk analysis. Cardiovascular and non-cardiovascular deaths were analyzed as competing events using cumulative incidence functions and Gray tests. Remarkably, the cumulative incidence of cardiovascular death showed no significant difference between treatment arms. Cardiovascular mortality occurred in 4.9% of balloon patients and 3.2% of stent patients, yielding a non-significant p-value of 0.589. This crucial finding demonstrates that drug-coated balloons provided cardiovascular safety comparable to drug-eluting stents. In contrast, the cumulative incidence of non-cardiovascular death differed dramatically between cohorts. Non-cardiovascular mortality reached 13.1% in the balloon group versus only 1.1% in the stent group, with a p-value of 0.002. Consequently, excess mortality in the balloon cohort arose almost entirely from non-cardiovascular conditions, particularly cancer progression. Therefore, the observed survival disadvantage reflects baseline oncologic vulnerability and operator selection bias rather than cardiovascular device failure.

Cardio-Oncology Decision-Making for Clinicians in India

These findings carry profound clinical relevance for interventional cardiologists and oncologists managing patients across India. As the burden of metabolic syndrome and cancer increases in India, clinicians frequently confront concurrent CAD and active malignancy. In Indian practice, dual antiplatelet therapy poses substantial bleeding risks during oncologic interventions, invasive biopsies, or chemotherapy-induced cytopenia. Consequently, Indian interventionalists frequently turn to drug-coated balloons to enable shorter antiplatelet regimens and avoid permanent metallic cages. However, this study demonstrates that patient survival is overwhelmingly governed by cancer severity rather than cardiac complications. Therefore, multidisciplinary tumor board discussions between cardiologists, oncologists, and hematologists are vital before undertaking coronary revascularization. Clinicians should not discard balloon angioplasty due to unadjusted mortality figures, because cardiac safety remains completely intact. Instead, interventional teams should integrate life expectancy, tumor stage, and anatomic complexity into their procedural algorithm. By personalizing revascularization strategies, Indian physicians can effectively safeguard cardiovascular stability while supporting uninterrupted cancer care.

Why did cancer patients treated with DCB exhibit lower overall survival?

The lower overall survival observed in the drug-coated balloon cohort was driven primarily by non-cardiovascular mortality, specifically cancer progression, rather than cardiovascular events. Patients selected for balloon angioplasty presented with more complex vascular disease and likely possessed more advanced oncologic staging. Because cardiovascular mortality did not differ significantly between groups, the survival gap reflects baseline oncologic fragility and operator selection bias rather than device-related failure.

Did cardiovascular death rates differ between DCB and DES treatments?

No, cardiovascular death rates showed no statistically significant difference between the two treatment strategies. Cumulative cardiovascular mortality reached 4.9% in the drug-coated balloon group and 3.2% in the drug-eluting stent group. This confirms that drug-coated balloons provided ischemic protection and cardiac safety comparable to modern stents. Interventional cardiologists can therefore safely employ balloon angioplasty without increasing the risk of cardiac mortality.

How should clinicians choose between DCB and DES in cancer patients?

Clinicians must evaluate bleeding vulnerability, planned oncologic therapies, cancer prognosis, and coronary lesion anatomy. When patients require urgent tumor resection, cancer chemotherapy, or suffer from severe thrombocytopenia, drug-coated balloons offer major advantages by shortening required antiplatelet therapy. Conversely, for large native vessels requiring structural support, drug-eluting stents remain appropriate. Multidisciplinary consultation between cardiologists and oncologists ensures revascularization choices align with overall life expectancy.

Disclaimer: This content is for informational and educational purposes only. It is not intended to substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Li XH et al. [Comparison of clinical outcomes of DCB angioplasty versus DES implantation in patients with recently diagnosed cancer and coronary artery disease undergoing PCI]. Zhonghua Yi Xue Za Zhi. 2026 Sep 08. doi: 10.3760/cma.j.cn112137-20260430-01184. PMID: 42706134.
2. Jeger RV, Eccleshall S, Wan Ahmad WA, et al. Drug-coated balloons for coronary artery disease: third report of the International DCB Consensus Group. JACC Cardiovasc Interv. 2020;13(12):1391-1402.
3. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361.